Lonapegsomatropin

Mechanism

A once-weekly growth hormone for children that's cleverly designed to release native, unmodified GH over the course of a week. Unlike somapacitan (which IS a modified GH), lonapegsomatropin is normal GH temporarily attached to a carrier that slowly releases it — so the body sees the same natural GH pulses it would expect. Approved for pediatric GH deficiency.

Effects

ENDOCRINE SYSTEM: Lonapegsomatropin (Skytrofa) is a once-weekly growth hormone prodrug utilizing TransCon (Transient Conjugation) technology developed by Ascendis Pharma. Unlike somapacitan (which is a modified GH analog), lonapegsomatropin consists of unmodified, native somatropin transiently bound to a methoxy-polyethylene glycol (mPEG) carrier via a proprietary linker that hydrolyzes slowly at physiological pH and temperature. This hydrolysis releases native, unmodified 191-amino acid GH continuously over the week — the same molecule the pituitary produces. The carrier (mPEG) and linker are inert and renally cleared. This "prodrug → native GH" approach is the key differentiator: the body sees the same GH it would produce endogenously, just delivered from a subcutaneous depot [RCT — heiGHt trial]. GROWTH AND DEVELOPMENT: In the pivotal heiGHt trial (Phase III, treatment-naive pediatric GHD), lonapegsomatropin demonstrated superior annualized height velocity compared to daily somatropin (Genotropin) at 52 weeks: 11.2 cm/year vs. 10.3 cm/year — a statistically significant ~0.9 cm/year advantage [RCT]. This superiority result was notable because long-acting GH formulations typically aim for non-inferiority. The fliGHt trial (single-arm) confirmed sustained growth through 2+ years. Bone maturation was proportional to height gain (no disproportionate bone age advancement, which would reduce final height potential). IGF-1 normalization was achieved with a weekly fluctuation pattern — peak IGF-1 around day 2-3, trough before next dose. PULSATILITY ADVANTAGE: A key theoretical argument for TransCon technology is that the continuous slow release of native GH from the subcutaneous depot may better approximate the physiological pulsatile GH secretion pattern than either daily injections (single bolus spike) or modified GH analogs (which have altered receptor binding kinetics). While exogenous GH delivery can never truly replicate the ultradian ~2-hour pulse frequency of endogenous secretion, the sustained release profile produces a more stable IGF-1 level throughout the week than bolus daily injections. Whether this translates to meaningful clinical advantages beyond the height velocity data in heiGHt remains to be determined. SAFETY: Side effects are consistent with the GH class — injection site reactions (erythema, pain — generally mild), headache, pyrexia, viral infections. Importantly, because the released molecule is native GH (not a modified analog), there is no theoretical concern about novel immunogenicity from an altered protein structure. Anti-drug antibodies were detected in a small percentage but were non-neutralizing and transient. No new safety signals compared to daily somatropin. Glucose metabolism effects were comparable to daily GH.

Practitioner Guide

DOSING: Currently FDA-approved only for pediatric GHD (approved January 2022, ages 1+). Dose: 0.24 mg/kg/week SC once weekly. Administer on the same day each week. If missed by ≤3 days, administer when remembered; if >3 days, skip and resume on the regular day. No dose adjustment needed for missed doses. ADMINISTRATION: Supplied as a two-chamber cartridge — one chamber contains lyophilized lonapegsomatropin, the other contains diluent. Reconstitute using the proprietary auto-injector device (Skytrofa), which mixes and injects in a single step. After reconstitution, use immediately or store refrigerated up to 4 hours. Store unreconstituted cartridges refrigerated (2-8°C). Inject SC into abdomen, thigh, or buttock. MONITORING: Same monitoring as daily somatropin — IGF-1 levels (draw at consistent timing relative to dose, typically mid-week at day 3-4), fasting glucose, thyroid function (free T4 — GH can unmask central hypothyroidism), morning cortisol, and bone age annually. IGF-1 target: age- and sex-appropriate normal range. If IGF-1 exceeds +2 SDS, consider dose reduction. Height velocity: expect 10-12 cm/year in first year for treatment-naive GHD children, with gradual deceleration in subsequent years (normal pattern). TRANSITIONING FROM DAILY GH: Convert total weekly somatropin dose using the 0.24 mg/kg/week target — this is typically close to 7x the daily dose. Monitor IGF-1 4-6 weeks after switch. CLINICAL POSITIONING: Lonapegsomatropin occupies a unique niche — it is the only weekly GH that releases native, unmodified somatropin. For practitioners who prioritize delivering native GH over a modified analog (somapacitan) or a persistent modified molecule (somatrogon), TransCon technology is compelling. The heiGHt trial superiority result (not just non-inferiority) over daily GH strengthens the case, though the ~0.9 cm/year advantage needs to be weighed in the context of a single trial. COMPARISON TO SOMAPACITAN: Both are weekly, both effective. Lonapegsomatropin releases native GH (purist argument); somapacitan is a modified analog with direct albumin binding (potentially simpler pharmacology). No head-to-head trial exists. Clinically, both achieve IGF-1 normalization and comparable growth. Device experience differs — Skytrofa requires reconstitution (slightly more complex), while somapacitan comes premixed. ADULT GHD: Not yet FDA-approved for adults, but Phase III trials (foresiGHt trial) are completed with positive results. Adult approval expected. COST: Premium pricing comparable to other weekly GH formulations — significantly more expensive per dose than daily biosimilar somatropin, but the adherence and convenience arguments apply. Insurance coverage varies and prior authorization is standard.

Evidence

• Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final Results

  Maniatis AK et al. (2025) — Horm Res Paediatr — PMID: 40049149

  In a multinational phase 3 extension for pediatric growth hormone deficiency, once-weekly lonapegsomatropin maintained growth through up to 6 years with mean height SDS approaching population norms, IGF-1 generally staying within 0-2 SDS, and no new major safety signals versus prior daily GH experience.

  moderate

Research Summary

TIER 1: heiGHt trial (2021, Deal et al.) — Phase III RCT in treatment-naive pediatric GHD: lonapegsomatropin 0.24 mg/kg/week vs. daily Genotropin 0.034 mg/kg/day. Superior annualized height velocity at 52 weeks (11.2 vs. 10.3 cm/year, p=0.0088). This is the landmark result — first weekly GH to show superiority over daily in a Phase III trial. fliGHt trial — single-arm Phase III in children previously on daily GH: maintained or improved growth velocity after switching. enliGHten trial — long-term open-label extension showing sustained efficacy through 3+ years with consistent safety. FDA approved for pediatric GHD (January 2022, Skytrofa). EMA approved (2022). TIER 2: TransCon technology platform publications characterizing the release kinetics, carrier pharmacology, and native GH bioactivity (Chatelain et al., 2017 — Phase II dose-finding). Pharmacokinetic/pharmacodynamic modeling comparing weekly IGF-1 profiles across different long-acting GH formulations. Post-hoc analyses of heiGHt examining subgroups (severity of GHD, age, gender). Systematic reviews of all long-acting GH products (Thornton et al., 2021). TIER 3: Expert consensus on positioning weekly GH in clinical practice. Pediatric endocrinology society position statements. Real-world data from early clinical use (limited, as product is relatively new). KEY FINDINGS: Lonapegsomatropin is the first weekly GH to demonstrate superiority over daily GH in growth velocity — a meaningful clinical differentiator. The TransCon native GH approach is scientifically elegant and avoids concerns about modified GH analogs having altered receptor dynamics. The trial program is well-designed with clear naming (heiGHt, fliGHt, enliGHten, foresiGHt). GAPS: No head-to-head trial vs. somapacitan or somatrogon. Adult GHD indication pending. Long-term final height data not yet available (critical question — does superior first-year velocity translate to superior final height?). Very long-term safety data still accumulating. Cost-effectiveness analyses limited. ACTIVE TRIALS: foresiGHt (adult GHD — Phase III complete, approval pending). Additional pediatric indications under investigation (Turner syndrome, SGA, Noonan syndrome, Prader-Willi). Long-term extension studies ongoing.